Avenue Therapeutics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Alix MacLean

Geschäftsführender

US$1.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	33.0%
Amtszeit als Geschäftsführer	2.2yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.6yrs

Jüngste Management Updates

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Alix MacLean im Vergleich zu den Einnahmen von Avenue Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$1m	US$400k	-US$10m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$516k	US$154k	-US$4m

Vergütung im Vergleich zum Markt: AlixDie Gesamtvergütung ($USD1.21M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD680.04K).

Entschädigung vs. Einkommen: AlixDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Alix MacLean (57 yo)

2.2yrs

Amtszeit

US$1,213,200

Vergütung

Dr. Alexandra MacLean, also known as Alix, MD, serves as Director of Kent Imaging Inc. since January 2021. She is Chief Executive Officer at Avenue Therapeutics, Inc. since August 01, 2022 and serves as it...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Alexandra MacLean	CEO & Director	2.2yrs	US$1.21m	keine Daten
David Jin	Interim CFO	2.6yrs	US$260.00k	0% $ 0
Lindsay Rosenwald	Executive Director	1.6yrs	US$104.00k	0.33% $ 10.8k
Scott Reines	Interim Chief Medical Officer	8.8yrs	US$123.12k	keine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrenes Management: ATXIDas Führungsteam des Unternehmens gilt als erfahren (2.2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Alexandra MacLean	CEO & Director	1.6yrs	US$1.21m	keine Daten
Lindsay Rosenwald	Executive Director	9.7yrs	US$104.00k	0.33% $ 10.8k
Jay Kranzler	Chairman of the Board	7.7yrs	US$212.19k	0.043% $ 1.4k
Neil Herskowitz	Non-Executive Independent Director	9.2yrs	US$164.00k	0.0084% $ 278.3
Faith Charles	Independent Director	2.4yrs	US$154.00k	0% $ 0
Curtis Oltmans	Independent Director	3.5yrs	US$154.00k	0.0031% $ 101.9

5.6yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: ATXIDie Vorstandsmitglieder gelten als erfahren (5.4 Jahre durchschnittliche Amtszeit).

Avenue Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Recent updates

New major risk - Financial position

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter